Clinical Trials
4 trialsNCT05733000 2023-03-10
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
Phase 2 Recruiting
NCT03370159 2018-08-01
CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 1/2 Withdrawn
NCT01931787 2018-07-03
CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 1 Completed
NCT01832857 2016-12-29
Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
Cornerstone Pharmaceuticals
Phase 2 Terminated